ISSN 1006-298X      CN 32-1425/R

导航

肾脏病与透析肾移植杂志 ›› 2013, Vol. 22 ›› Issue (1): 21-25.

• 论文 • 上一篇    下一篇

连续性静脉-静脉血液滤过对急性肾损伤患者胱抑素C浓度的影响

  

  • 出版日期:2013-02-28 发布日期:2013-03-19

Effect of Continuous Renal Replacement Therapy in Patients with Acute Kidney Injury on the Serum Levels of Biomarkers usually used to Indicate Renal Function

  • Online:2013-02-28 Published:2013-03-19

摘要:

摘要 目的:观察连续性静脉-静脉血液滤过(CVVH)置换剂量和持续时间对急性肾损伤(AKI)伴少尿患者血清肾功能标志物的影响,。方法:本研究为观察性研究,将AKI伴少尿需行肾脏替代治疗患者纳入研究,给予CVVH连续治疗24h以上,置换剂量分别为2L/h或4L/h。分别于CVVH治疗前及治疗第4、12、24h抽取滤器前血液,第4h抽取滤器后血液及超滤液,检测肾功能标志物包括尿素(Urea)、肌酐(SCr)和胱抑素C(Cys C)的浓度。比较不同置换剂量和持续时间下上述各指标的下降率,并计算滤器清除率和浓度时间曲线下面积(AUC)。结果:共纳入15例患者,其中2L/h剂量组7例,4L/h剂量组8例,两组间年龄构成、性别比例均无差异,CVVH治疗前2L/h剂量组Urea、SCr浓度均低于4L/h剂量组(P<0.05),Cys C浓度差异无统计学意义。2L/h剂量组CVVH治疗第4、12、24h滤器前血清Urea浓度较治疗前平均下降分别为14.0%、38.0%、50.0%; SCr浓度平均下降分别为13.1%、30.8%、47.3%;血清Cys C浓度平均下降分别为8.4%、25.0%、33.0%。第12和24h血清Cys C浓度下降率均低于同期Urea、SCr浓度下降率(P均<0.05)。2L/h剂量组Urea、SCr和Cys C清除率分别为26.1±8.3 ml/min、24.9±6.4 ml/min和10.1±4.9ml/min,Urea、SCr及Cys C的AUC分别为0.306 mg/(L.h)、0.252 mg/(L.h)及0.190 mg/(L.h)。4L/h剂量组CVVH治疗第4、12、24h滤器前血清Urea浓度较治疗前平均下降分别为12.2%、43.3%、58.7%,SCr浓度平均下降分别为14.8%、35.3%、50.0%,血清Cys C浓度平均下降分别为16.1%、23.1%、31.4%。第12和24h血清Cys C浓度下降率均低于同期Urea、SCr浓度下降率(P均<0.05)。4L/h剂量组对Urea、SCr和Cys C清除率分别为43.6±3.2 ml/min、42.4±7.9 ml/min和23.7±8.0ml/min,Urea、SCr及Cys C的AUC分别为0.271 mg/(L.h)、0.216 mg/(L.h)及0.310 mg/(L.h)。 结论:CVVH置换剂量和持续时间对AKI患者的血清肾功能标志物浓度均有不同程度的影响,血清Cys C浓度变化及清除率均远低于Urea、SCr。

关键词: 连续性肾脏替代治疗   , 连续性静脉-静脉血液滤过   , 急性肾损伤

Abstract:

ABSTRACT   Objective: Continuous veno-venous hemofiltration (CVVH) can affect the serum concentrations of usually used biomarkers to indicate renal function, like urea, creatinine (SCr) and cystatin C (Cys C). In this study, what extent (dose and duration) CVVH could affect the concentrations of urea, SCr and Cys C independent on renal function change was investigated. Methodology: Fifteen patients with oliguric acute AKI requiring CVVH were enrolled. Seven of them received CVVH in predilution mode at dose of 2L/hr and eight received CVVH in predilution mode at dose of 4L/hr. Samples were obtained from the afferent and efferent lines of the extracorporeal circuit and from the ultrafiltrate line at 4 different time points (0, 4, 12 and 24h) for measurement of urea, SCr and Cys C. The changes of serum levels of biomarkers over time, clearance of biomarkers and area under the curve (AUC) were analyzed. Results: The serum levels of urea, SCr and Cys C were gradually decreased at 4, 12 and 24hr during CVVH at dose of 2L/hr. The mean decreases of urea, SCr and Cys C at 24hr were 50.0%, 47.3% and 33.0% respectively. The decreases of Cys C at 24hr were significantly less than that of SCr and urea (both P<0.05). The mean clearance of urea, SCr and Cys C were 26.1, 24.9 and 10.1mL/min, and AUC (mg/L.h) were Urea 0.306, SCr 0.252 and Cys C 0.190 respectively. The serum levels of urea, SCr and Cys C were gradually decreased at 4, 12 and 24h during CVVH at dose of 4L/hr. The mean decreases of urea, SCr and Cys C at 24hr were 58.7%, 50.0% and 31.4% respectively. The decreases of Cys C at 24hr were significantly less than that of SCr and urea (both P<0.05). The mean clearance of urea, SCr and Cys C were 43.6, 42.4 and 23.7mL/min, and AUC (mg/L.h) were Urea 0.271, SCr 0.216 and Cys C 0.310 respectively.  Conclusion: The alteration of serum levels of Cys C during CVVH is comparable with SCr and urea.

Key words: continuous renal replacement therapy  , continuous veno-venous hemofiltration  , acute kidney injury